vs
Side-by-side financial comparison of Alignment Healthcare, Inc. (ALHC) and BioNTech SE (BNTX). Click either name above to swap in a different company.
BioNTech SE is the larger business by last-quarter revenue ($1.5B vs $1.0B, roughly 1.5× Alignment Healthcare, Inc.). Alignment Healthcare, Inc. runs the higher net margin — -1.1% vs -1.9%, a 0.8% gap on every dollar of revenue.
Alignment Healthcare, Inc. is a U.S.-based healthcare provider offering Medicare Advantage plans for seniors. It adopts a value-based care model, partnering with local providers to deliver personalized coordinated medical services, prescription drug coverage and supplemental benefits to members across multiple U.S. states.
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
ALHC vs BNTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.5B |
| Net Profit | $-11.0M | $-28.7M |
| Gross Margin | — | — |
| Operating Margin | -1.0% | -3.1% |
| Net Margin | -1.1% | -1.9% |
| Revenue YoY | 44.4% | — |
| Net Profit YoY | 64.6% | — |
| EPS (diluted) | $-0.04 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | — | ||
| Q3 25 | $993.7M | $1.5B | ||
| Q2 25 | $1.0B | $260.8M | ||
| Q1 25 | $926.9M | — | ||
| Q4 24 | $701.2M | — | ||
| Q3 24 | $692.4M | $1.2B | ||
| Q2 24 | $681.3M | — | ||
| Q1 24 | $628.6M | — |
| Q4 25 | $-11.0M | — | ||
| Q3 25 | $3.7M | $-28.7M | ||
| Q2 25 | $15.7M | $-386.6M | ||
| Q1 25 | $-9.1M | — | ||
| Q4 24 | $-31.1M | — | ||
| Q3 24 | $-26.4M | $198.1M | ||
| Q2 24 | $-24.0M | — | ||
| Q1 24 | $-46.5M | — |
| Q4 25 | -1.0% | — | ||
| Q3 25 | 0.8% | -3.1% | ||
| Q2 25 | 2.2% | -192.1% | ||
| Q1 25 | -0.6% | — | ||
| Q4 24 | -3.2% | — | ||
| Q3 24 | -2.8% | 0.8% | ||
| Q2 24 | -2.7% | — | ||
| Q1 24 | -6.5% | — |
| Q4 25 | -1.1% | — | ||
| Q3 25 | 0.4% | -1.9% | ||
| Q2 25 | 1.5% | -148.2% | ||
| Q1 25 | -1.0% | — | ||
| Q4 24 | -4.4% | — | ||
| Q3 24 | -3.8% | 15.9% | ||
| Q2 24 | -3.5% | — | ||
| Q1 24 | -7.4% | — |
| Q4 25 | $-0.04 | — | ||
| Q3 25 | $0.02 | — | ||
| Q2 25 | $0.07 | — | ||
| Q1 25 | $-0.05 | — | ||
| Q4 24 | $-0.15 | — | ||
| Q3 24 | $-0.14 | — | ||
| Q2 24 | $-0.13 | — | ||
| Q1 24 | $-0.25 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $604.2M | — |
| Total DebtLower is stronger | $323.2M | — |
| Stockholders' EquityBook value | $179.3M | — |
| Total Assets | $1.1B | — |
| Debt / EquityLower = less leverage | 1.80× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $604.2M | — | ||
| Q3 25 | $644.1M | — | ||
| Q2 25 | $503.8M | — | ||
| Q1 25 | $479.5M | — | ||
| Q4 24 | $470.6M | — | ||
| Q3 24 | $381.0M | — | ||
| Q2 24 | $363.7M | — | ||
| Q1 24 | $301.7M | — |
| Q4 25 | $323.2M | — | ||
| Q3 25 | $322.7M | — | ||
| Q2 25 | $322.3M | — | ||
| Q1 25 | $321.9M | — | ||
| Q4 24 | $321.4M | — | ||
| Q3 24 | $212.0M | — | ||
| Q2 24 | $211.7M | — | ||
| Q1 24 | $162.0M | — |
| Q4 25 | $179.3M | — | ||
| Q3 25 | $161.9M | — | ||
| Q2 25 | $141.0M | — | ||
| Q1 25 | $108.1M | — | ||
| Q4 24 | $99.9M | — | ||
| Q3 24 | $114.5M | — | ||
| Q2 24 | $123.7M | — | ||
| Q1 24 | $130.9M | — |
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $895.6M | — | ||
| Q4 24 | $782.1M | — | ||
| Q3 24 | $692.3M | — | ||
| Q2 24 | $716.3M | — | ||
| Q1 24 | $633.2M | — |
| Q4 25 | 1.80× | — | ||
| Q3 25 | 1.99× | — | ||
| Q2 25 | 2.29× | — | ||
| Q1 25 | 2.98× | — | ||
| Q4 24 | 3.22× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 1.71× | — | ||
| Q1 24 | 1.24× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-50.4M | — |
| Free Cash FlowOCF − Capex | $-55.4M | — |
| FCF MarginFCF / Revenue | -5.5% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $113.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-50.4M | — | ||
| Q3 25 | $144.6M | — | ||
| Q2 25 | $29.1M | — | ||
| Q1 25 | $16.6M | — | ||
| Q4 24 | $-8.7M | — | ||
| Q3 24 | $26.2M | — | ||
| Q2 24 | $23.5M | — | ||
| Q1 24 | $-6.2M | — |
| Q4 25 | $-55.4M | — | ||
| Q3 25 | $139.1M | — | ||
| Q2 25 | $21.1M | — | ||
| Q1 25 | $8.4M | — | ||
| Q4 24 | $-18.0M | — | ||
| Q3 24 | $16.9M | — | ||
| Q2 24 | $11.8M | — | ||
| Q1 24 | $-17.4M | — |
| Q4 25 | -5.5% | — | ||
| Q3 25 | 14.0% | — | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 0.9% | — | ||
| Q4 24 | -2.6% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 1.7% | — | ||
| Q1 24 | -2.8% | — |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 0.9% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 1.3% | — | ||
| Q2 24 | 1.7% | — | ||
| Q1 24 | 1.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 38.77× | — | ||
| Q2 25 | 1.86× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
